CalciMedica (NASDAQ:CALC – Get Free Report) released its earnings results on Thursday. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.14, Zacks reports.
CalciMedica Stock Up 5.5 %
Shares of CalciMedica stock opened at $2.10 on Thursday. The business has a fifty day simple moving average of $2.43 and a 200-day simple moving average of $3.19. The firm has a market cap of $28.31 million, a price-to-earnings ratio of -1.94 and a beta of 1.20. CalciMedica has a fifty-two week low of $1.83 and a fifty-two week high of $6.27.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of CalciMedica in a research report on Tuesday, March 4th.
About CalciMedica
CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Read More
- Five stocks we like better than CalciMedica
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- How China’s Recovery Could Boost These 3 Platinum Plays
- How to buy stock: A step-by-step guide for beginners
- Fortinet: A Top Cybersecurity Stock With Growth Catalysts
- The Basics of Support and Resistance
- 4 Reasons Amazon Stock Can’t Be Ignored Right Now
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.
